Product Program year 2019 Source: CMS Open Payments

Ambien

Drug Sleep Disorders

NDC 0024-5401-31

Open in the dashboard

General payments

$25,956

10 payments

Research payments

$0

0 payments

Through program year 2019, $25,956 in general payments and $0 in research payments were reported against Ambien (Sleep Disorders).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2019 General $25,956 10

Breakdown

Who paid General payments · program year 2019
  1. Sanofi-Aventis U.S. LLC $25,956 10 payments
Top recipients General payments · program year 2019
  1. Phyllis Zee Sleep Medicine · Chicago, IL $18,184 70% · 6 payments
  2. Mark Frye Psychiatry · Rochester, MN $7,772 30% · 4 payments

Each share is of general payments naming this product in 2019.

Specialties paid General payments · program year 2019
  1. Sleep Medicine Psychiatry & Neurology $18,184 70% · 1 practitioner
  2. Psychiatry Psychiatry & Neurology $7,772 30% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2019
  1. Illinois $18,184 70% · 1 recipient
  2. Minnesota $7,772 30% · 1 recipient

Each share is of general payments naming this product in 2019 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

7,962

Prescriptions dispensed, refills included

Drug cost

$5,169,802

Paid at the pharmacy, in all

Medicare Part D drugs matched to AMBIEN, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Ambien Zolpidem Tartrate Same name 376 5,214 $3,411,231
Ambien Cr Zolpidem Tartrate Similar name 218 2,748 $1,758,571

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 196 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Giovanny Nunez Psychiatry NY 156 $91,895 None on record
Valeri Kazakov Internal Medicine NY 71 $45,619 None on record
Fernando Taveras Psychiatry NY 59 $33,246 None on record
Vadim Azbel Psychiatry NY 48 $28,704 None on record
Michael Barrett Family Practice SC 41 $25,637 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 196 with Patron
10 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record